San Francisco, CA. November 9-13, 2018.
Medscape Medical News, November 2, 2018
Fatty Liver Disease in the Spotlight at The Liver Meeting
Current and future treatments for fatty liver disease, particularly nonalcoholic steatohepatitis, the most prevalent liver disease in the United States, will be explored at The Liver Meeting....
Results from phase 2 studies of drugs for nonalcoholic steatohepatitis — Mgl-3196 (Madrigal Pharmaceuticals), obeticholic acid (Ocaliva/Intercept Pharmaceuticals), GS-9674 (Gilead Sciences), NGM282 (NGM Bio), arachidyl amido cholanoic acid (Aramchol, Galmed Pharmaceuticals), and tropifexor (Novartis) — will be presented.Read More.....
Researchers are figuring out how to make better use of the treatments they have on hand, particularly for hepatitis C and hepatocellular carcinoma, said Kimberly Brown, MD, from the Henry Ford Health System in Detroit, who is cochair of the scientific programming committee for the meeting....
Recommended Reading
Medscape Gastroenterology, May 18, 2018
No comments:
Post a Comment